NCT00175565View on ClinicalTrials.gov

Inhaled Steroid Reduces Systemic Inflammation in COPD

PHASE4CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

January 31, 2002

Study Completion Date

July 31, 2003

Conditions

Chronic Obstructive Pulmonary DiseaseEmphysemaChronic Bronchitis

Interventions

DRUG

inhaled fluticasone 500 mcg b.i.d.

Trial Locations (2)

T6G 2R7

University of Alberta, Edmonton

V6Z 1Y7

University of British Columbia, Vancouver

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of British Columbia

OTHER